Brain Scan ARIA Segmentation With ML for Limited Annotation Data
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to accurately segment and detect amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients, particularly due to the challenges of limited training data and susceptibility to errors in pixel-wise or voxel-wise annotations, leading to potential misdiagnosis and reduced inter-rater agreement.
Innovation Solution
Utilizing machine-learning models, specifically semantic image segmentation and classification models, to segment and detect ARIA in brain scans, employing techniques like multi-task learning, transfer learning, and contrastive learning, allowing for separate training of segmentation and classification tasks to improve accuracy and efficiency with limited data.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods (PET, SPECT, MRI) are used to detect ARIA, then imaging capability is provided, but quantitative measurement of amyloid burden and treatment response is insufficient
Solution Approach 1:
The patent introduces a novel radiotracer (intermediary substance) that specifically binds to amyloid plaques in the brain. This radiotracer serves as a mediator between the imaging system and the amyloid burden, enabling quantitative measurement. The radiotracer's binding characteristics provide a direct measure of amyloid load, resolving the difficulty in quantifying amyloid burden using conventional imaging methods.
Solution Approach 2:
The patent changes the imaging parameter by using a new radiotracer with specific binding characteristics to amyloid plaques. This parameter change enables quantitative measurement of amyloid burden through the radiotracer's binding affinity and signal intensity, transforming qualitative imaging into quantitative measurement capability.
2Reliability
If conventional imaging methods are used, then imaging is available, but assessment of treatment response is unreliable
Solution Approach 1:
The patent establishes a feedback mechanism where the radiotracer binding signal provides direct information about amyloid burden changes in response to treatment. By measuring the radiotracer signal before and after treatment, clinicians can reliably assess treatment response through quantitative changes in binding intensity, enabling precise monitoring of therapeutic effectiveness.
3Measurement precision
If ADAMTS13 activity is measured using conventional methods, then activity is detected, but measurement precision and reproducibility are insufficient
Solution Approach 1:
The patent replaces conventional mechanical/chemical measurement methods with a radiotracer-based imaging approach. The radiotracer binding signal provides a direct, quantifiable measure of ADAMTS13 activity without requiring complex in vitro assays, thereby improving measurement precision while reducing operational complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach provides accurate segmentation and classification of ARIA, enabling dosage adjustments and treatment recommendations, reducing the risk of ARIA-related side effects and improving clinical management of Alzheimer's disease.
Implementation Method 1
a method of quantifying amyloid-related imaging abnormalities (ARIA) in a patient comprising: providing a radiotracer that binds to amyloid plaques in a brain of the patient
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A
AI summary
Methods for quantifying amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models. The one or more machine-learning models are trained to generate a segmentation map based on the set of one or more brain-scan images, the segmentation map including a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map. The one or more machine-learning models are further trained to generate a classification score based on the segmentation map. The method thus includes detecting ARIA in the brain of the patient based on the classification score.